

# Cagatay Arslan

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4207427/cagatay-arslan-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51  
papers

566  
citations

15  
h-index

22  
g-index

55  
ext. papers

631  
ext. citations

3.9  
avg, IF

3.55  
L-index

#	Paper	IF	Citations
51	Modified docetaxel, cisplatin, and 5-fluorouracil combination regimen and capecitabine maintenance in metastatic gastric cancer: toxicity and efficacy results.. <i>Supportive Care in Cancer</i> , <b>2022</b> ,	3.9	2
50	Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database. <i>Future Oncology</i> , <b>2021</b> , 17, 4861-4869	3.6	1
49	Merkel cell carcinoma in Turkey: A multicentric study.. <i>Journal of Cancer Research and Therapeutics</i> , <b>2021</b> , 17, 1525-1529	1.2	
48	Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study). <i>Journal of Oncology Pharmacy Practice</i> , <b>2020</b> , 26, 1583-1589	1.7	1
47	The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer. <i>Journal of Oncology Pharmacy Practice</i> , <b>2020</b> , 26, 1110-1116	1.7	10
46	Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy. <i>Expert Review of Anticancer Therapy</i> , <b>2019</b> , 19, 589-601	3.5	5
45	Biweekly cetuximab in combination with platinum and 5-fluorouracil in metastatic head and neck carcinoma. <i>Indian Journal of Cancer</i> , <b>2019</b> , 56, 4-8	0.9	1
44	An update on the currently available and future chemotherapy for treating bone metastases in breast cancer patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 1305-1316	4	5
43	Merkel cell carcinoma in Turkey: A multicentric study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e21591-e21591		
42	Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications?. <i>World Journal of Urology</i> , <b>2017</b> , 35, 479-480	4	
41	Thrombin activatable fibrinolysis inhibitor, tissue factor pathway inhibitor, and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 615-615	2.2	
40	Glomus tüberiklerinde cerrahi tedaviye selektif boyun diseksiyonu eklemenin metastazlar saptamaya ve adjuvan tedavi seçimine olan katkıları. <i>Ordu Üniversitesi Tıp Fakültesi Dergisi</i> , <b>2016</b> , 41, 71-73		
39	Bisphosphonate therapy in metastatic carcinoma patients with chronic renal failure: are bisphosphonates an enemy or crony?. <i>Supportive Care in Cancer</i> , <b>2015</b> , 23, 1489-91	3.9	3
38	Advances in PARP inhibitors for the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 2751-8	4	34
37	A case of rectal carcinoma with skin and bone marrow metastasis with concurrent extensive visceral involvement; unusual and dismal co-incidence. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2015</b> , 9, 727-30	4.2	1
36	Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer. <i>Oncology Letters</i> , <b>2015</b> , 10, 2598-2602	2.6	9
35	Brain specific progression free survival (bsPFS) according to breast cancer subtypes in patients with brain metastases.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e13040-e13040	2.2	1

34	Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 1643-58	4	16
33	Current and future systemic treatment options in metastatic pancreatic cancer. <i>Journal of Gastrointestinal Oncology</i> , <b>2014</b> , 5, 280-95	2.8	29
32	A case of ulcerative colitis with digital arterial thrombosis. <i>Turkish Journal of Gastroenterology</i> , <b>2014</b> , 25, 96-9	1	2
31	Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 1709-15	2.8	23
30	Secondary haematological malignancies in the BCIRG 001 study. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, e87-8	21.7	2
29	Increased mean corpuscular volume of erythrocytes predicts the response to metronomic cyclophosphamide, capecitabine and bevacizumab treatment: is it true for capecitabine treatment or more?. <i>Breast</i> , <b>2012</b> , 21, 612-3	3.6	1
28	Frequency of HCV infection in renal cell carcinoma patients. <i>Medical Oncology</i> , <b>2012</b> , 29, 1892-5	3.7	8
27	Screening colonoscopy participation in Turkish colorectal cancer patients and their first degree relatives. <i>Asian Pacific Journal of Cancer Prevention</i> , <b>2012</b> , 13, 2829-32	1.7	11
26	Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature. <i>Expert Opinion on Therapeutic Targets</i> , <b>2011</b> , 15, 21-30	6.4	46
25	Increased Mean Corpuscular Volume of Erythrocytes during Capecitabine Treatment: A Simple Surrogate Marker for Clinical Response. <i>Tumori</i> , <b>2011</b> , 97, 711-716	1.7	6
24	Zoledronic acid and atrial fibrillation in cancer patients. <i>Supportive Care in Cancer</i> , <b>2011</b> , 19, 425-30	3.9	19
23	Acute promyelocytic leukemia in a young patient with breast cancer. <i>Medical Oncology</i> , <b>2011</b> , 28, 249-50	3.7	1
22	Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer. <i>Medical Oncology</i> , <b>2011</b> , 28 Suppl 1, S75-9	3.7	7
21	Emerging drugs in metastatic breast cancer: an update. <i>Expert Opinion on Emerging Drugs</i> , <b>2011</b> , 16, 647-67	3.7	7
20	Gastric cancer after cadaveric liver transplantation in a patient with autoimmune hepatitis: A case report and review of the literature. <i>Turkish Journal of Gastroenterology</i> , <b>2011</b> , 22, 73-6	1	5
19	Increased mean corpuscular volume of erythrocytes during capecitabine treatment: a simple surrogate marker for clinical response. <i>Tumori</i> , <b>2011</b> , 97, 711-6	1.7	3
18	Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e99; author reply e100	2.2	1
17	Estrogen receptor immunohistochemistry cutoff value: standardization is needed. <i>Human Pathology</i> , <b>2010</b> , 41, 150; author reply 150-1	3.7	1

16	Systemic treatment in breast-cancer patients with brain metastasis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2010</b> , 11, 1089-100	4	34
15	The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives. <i>Expert Opinion on Pharmacotherapy</i> , <b>2010</b> , 11, 2715-25	4	6
14	The effect on prognosis of postoperative CA 19-9 level in patients with pancreatic cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2010</b> , 33, 320; author reply 320	2.7	1
13	Serum levels of CEA and CA 15-3 in triple-negative breast cancer at the time of diagnosis. <i>Medical Oncology</i> , <b>2010</b> , 27, 1429	3.7	5
12	Other malignancies in patients with breast cancer: a single institute experience. <i>Medical Oncology</i> , <b>2010</b> , 27, 1434-5	3.7	
11	Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. <i>Medical Oncology</i> , <b>2010</b> , 27, 1436-7	3.7	21
10	Risk of venous thromboembolism with bevacizumab in cancer patients. <i>JAMA - Journal of the American Medical Association</i> , <b>2009</b> , 301, 1435; author reply 1435-6	27.4	5
9	Pharmacotherapy of triple-negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2009</b> , 10, 2081-93		26
8	Letter to the editor. Women with HER2-positive metastatic breast cancer have significantly longer survival after diagnosis of brain metastasis(BM) than those with HER2-negative disease. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2009</b> , 32, 226	2.7	
7	Level of oxidative stress and damage in erythrocytes in apprentices indirectly exposed to lead. <i>Pediatrics International</i> , <b>2008</b> , 50, 45-50	1.2	27
6	Osteosclerosis due to endemic fluorosis. <i>Science of the Total Environment</i> , <b>2007</b> , 373, 43-8	10.2	53
5	The effect of long-term low-dose lead exposure on thyroid function in adolescents. <i>Environmental Research</i> , <b>2006</b> , 101, 140-5	7.9	56
4	Protective role of erdosteine on vancomycin-induced oxidative stress in rat liver. <i>Molecular and Cellular Biochemistry</i> , <b>2006</b> , 291, 155-60	4.2	16
3	Assessment of aortic stiffness and ventricular diastolic functions in patients with Behçet's disease. <i>Rheumatology International</i> , <b>2005</b> , 25, 447-51	3.6	25
2	Thrombocytosis in solid tumors: review of the literature. <i>Turkish Journal of Haematology</i> , <b>2005</b> , 22, 59-64	0.9	3
1	Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema (RS3PE syndrome): a report of two cases and review of the literature. <i>Rheumatology International</i> , <b>2004</b> , 24, 234-7	3.6	26